32 results on '"Atzori, F."'
Search Results
2. Status of PI3K inhibition and biomarker development in cancer therapeutics
3. 696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
4. 1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
5. 349P The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
6. 800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy
7. 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study
8. 736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial
9. Prolonged neoadjuvant chemotherapy in locally advanced breast cancer patients: A prognostic role to disease free survival (DFS) and overall suvival (OS)?
10. CISPLATIN-ASSOCIATED ANEMIA: A TWO-PRONGED EFFECT?
11. Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study
12. Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience
13. Safe chemotherapy for treating early breast cancer in G6PD-deficient patients
14. Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy
15. Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study
16. CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
17. Medical management of malignant bowel obstruction: our center experience
18. Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience
19. Management of breakthrough cancer pain in patients with oral mucositis
20. 207P - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study
21. P-296 - Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience
22. 105P - Safe chemotherapy for treating early breast cancer in G6PD-deficient patients
23. Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: PRO-BMI study
24. 880P - Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy
25. 58P - Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study
26. U10 - Management of breakthrough cancer pain in patients with oral mucositis
27. U3 - Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience
28. B1* - CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
29. 905P - CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
30. C17 - Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: PRO-BMI study
31. Prognostic Factors and Validation of Prognostic Nomograms in Patients (PTS) Treated with 3 Targeted Therapies (TTS) for Metastatic Renal Cell Carcinoma (MRCC): Results from an Italian Survey
32. 836P - Prognostic Factors and Validation of Prognostic Nomograms in Patients (PTS) Treated with 3 Targeted Therapies (TTS) for Metastatic Renal Cell Carcinoma (MRCC): Results from an Italian Survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.